|Market Cap||2,502 Cr||EPS||3.3||High||164.5|
|Stock P/E||48.0||Net Profit Margin||2.0||Low||158.5|
Camlin Fine Sciences Price chart
|Market Cap||2,502 Cr||ROE||10.6%|
|P/B Ratio||4.0||Dividend Yield||0.0%|
|Industry P/E||56.9||Book Value||39.3|
About the Company
Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in
Company changed its name from Camlin Fine Chemicals Ltd. to Camlin Fine Sciences Ltd.
Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified.
a) Food Ingredients –
Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone)
Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole)
b) Sweetener -
Sucralose FCC V
c) Active Pharmaceutical Ingredients -
- Miconazole Nitrate B.P. / USP
- Clotrimazole B.P. / USP
- Amlodipine Besilate E.P
- Amlodipine Salts
- Advance intermediate of Amlodipine
- Intermediate of Miconazole Nitrate
d) Super Absorbent Polymer
- Chemolutions Chemicals: Specialty Chemical Intermediates
- Sangam Laboratories: Nutraceuticals
- Fine Renewable Energy.
- Fine LifeStyle Brands: Luxury Fashion Brands
On 6th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in
On 7th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates.
As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in
On 25th February 2008: Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur.
On 12th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets.
|Parent Organisation||Camlin Fine Sciences Ltd.||Managing Director||Nirmal V Momaya|
All values are in Rs Cr
|Company||52 Week||Market Price||P/E Ratio||Financials||Share Holding|